GlassScriptPhysician profile
Robert B Kroopnick
NPI 1013936327
$5,388.73
in general payments reported to CMS, 2019-2025
40 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,055 · 2021: $1,823 · 2022: $694 · 2023: $326 · 2024: $91.13 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.91 | 2019-2025 | |
| Novo Nordisk INC | $525.91 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $477.80 | 2019-2025 | Breztri |
| Esperion Therapeutics, INC. | $435.66 | 2020-2021 | |
| Glaxosmithkline, LLC. | $343.35 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $335.03 | 2019-2022 | |
| Lilly USA, LLC | $270.13 | 2019-2025 | Kisunla, Trulicity, Mounjaro |
| Astellas Pharma US INC | $234.89 | 2019-2023 | Veozah |
| Mannkind Corporation | $194.67 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $164.26 | 2020-2024 | Capvaxive |
| Sanofi-Aventis U.S. LLC | $159.71 | 2019-2022 | |
| Amgen INC. | $134.69 | 2019-2020 | |
| Amarin Pharma, INC. | $128.25 | 2020-2021 | |
| Urovant Sciences INC | $120.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.49 | 2020-2023 | Synjardy, Jardiance, Tradjenta |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kroopnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.